<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777268</url>
  </required_header>
  <id_info>
    <org_study_id>Infacort 001</org_study_id>
    <nct_id>NCT02777268</nct_id>
  </id_info>
  <brief_title>Comparison of Pharmacokinetics of Infacort® Versus Immediate-release Hydrocortisone</brief_title>
  <official_title>A Single Centre, Open Label, Randomised, Crossover Study in Dexamethasone-suppressed Healthy Adult Male Volunteers to Compare the Pharmacokinetics of Infacort® Versus Immediate-release Hydrocortisone Tablets at a Single Dose of 10 mg and to Evaluate the Dose Proportionality of Infacort® at Doses of 0.5 mg, 2 mg, 5 mg and 10 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diurnal Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Simbec Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Diurnal Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a single centre, open-label, randomised, 5-way crossover study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a single centre, open-label, randomised, 5-way crossover study design to compare the
      PK of Infacort® versus immediate-release hydrocortisone tablets and to evaluate the dose
      proportionality of 0.5 mg, 2 mg, 5 mg and 10 mg Infacort®. The study was conducted in 1
      cohort of 16 healthy male subjects and comprised a Screening Visit, 5 treatment periods
      (Treatment Periods 1 to 5) and a Post-study Visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Infacort vs Hydrocortisone</measure>
    <time_frame>-1h, -0.5h, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, 6h, 6.5h, 7h, 7.5h, 8h, 9h, 10h, 11h, 12h</time_frame>
    <description>To compare the Cmax of Infacort® versus immediate-release hydrocortisone in a single dose of 10 mg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration (Tmax) of Infacort vs Hydrocortisone</measure>
    <time_frame>-1h, -0.5h, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, 6h, 6.5h, 7h, 7.5h, 8h, 9h, 10h, 11h, 12h</time_frame>
    <description>To compare the Tmax of Infacort® versus immediate-release hydrocortisone in a single dose of 10 mg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC0-t) of Infacort vs Hydrocortisone</measure>
    <time_frame>-1h, -0.5h, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, 6h, 6.5h, 7h, 7.5h, 8h, 9h, 10h, 11h, 12h</time_frame>
    <description>To compare the AUC0-t of Infacort® versus immediate-release hydrocortisone in a single dose of 10 mg. AUC0-t represents the total exposure to drug over time, hence the reporting of a single value below.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Infacort at Doses of 0.5, 2, 5 and 10 mg</measure>
    <time_frame>-1h, -0.5h, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, 6h, 6.5h, 7h, 7.5h, 8h, 9h, 10h, 11h, 12h</time_frame>
    <description>To determine the dose proportionality for Infacort® at doses of 0.5 mg, 2 mg, 5 mg and 10 mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Infacort at Doses of 0.5, 2, 5 and 10 mg</measure>
    <time_frame>-1h, -0.5h, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, 6h, 6.5h, 7h, 7.5h, 8h, 9h, 10h, 11h, 12h</time_frame>
    <description>To determine the dose proportionality for Infacort® at doses of 0.5 mg, 2 mg, 5 mg and 10 mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC0-t) of Infacort at Doses of 0.5, 2, 5 and 10 mg</measure>
    <time_frame>1 day</time_frame>
    <description>To determine the dose proportionality for Infacort® at doses of 0.5 mg, 2 mg, 5 mg and 10 mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) as Assessed by Medical Dictionary for Regulatory Activities (MedDRA) Dictionary, Version 16.0.</measure>
    <time_frame>1 day</time_frame>
    <description>To assess the safety and tolerability of Infacort® throughout the study. For a full list of TEAEs per arm, please refer to the Adverse Events section.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Infacort 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multi-particulate granules from 1 (0.5 mg) capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infacort 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multi-particulate granules from 1 (2 mg) capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infacort 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multi-particulate granules from 1 (5 mg) capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infacort 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multi-particulate granules from 1 (10 mg) capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrocortisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 (10 mg) tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infacort</intervention_name>
    <description>Multi-particulate granules</description>
    <arm_group_label>Infacort 0.5 mg</arm_group_label>
    <arm_group_label>Infacort 2 mg</arm_group_label>
    <arm_group_label>Infacort 5 mg</arm_group_label>
    <arm_group_label>Infacort 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Hydrocortisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers between 18 and 60 years of age, inclusive (at Screening
             Visit).

          -  Subjects with a Body Mass Index (BMI) of 21-28.

          -  Subjects with no clinically significant abnormal serum biochemistry, haematology and
             urine examination values within 14 days prior to the first dose of investigational
             medicinal product (IMP).

          -  Subjects with a negative urinary drugs of abuse screen determined within 14 days prior
             to the first dose of IMP. A positive alcohol test may have been repeated at the
             discretion of the Investigator.

          -  Subjects with negative human immunodeficiency virus (HIV) and hepatitis B surface
             antigen (Hep B) and hepatitis C virus antibody (Hep C) results.

          -  Subjects with no clinically significant abnormalities in 12-lead electrocardiogram
             (ECG) determined within 14 days prior to the first dose of IMP.

          -  Subjects with no clinically-significant deviation outside the normal ranges for blood
             pressure and pulse measurements.

          -  Subjects (unless anatomically sterile or where abstaining from sexual intercourse was
             in-line with the preferred and usual lifestyle of the subject) and sexual partners
             used effective contraception methods during the trial and for 3 months after the last
             dose of IMP, for example; oral contraceptive + condom, intra-uterine device (IUD) +
             condom or diaphragm with spermicide + condom.

          -  Subjects were available to complete the study.

          -  Subjects satisfied a medical examiner about their fitness to participate in the study.

          -  Subjects provided written informed consent to participate in the study.

        Exclusion Criteria:

          -  A clinically significant history of gastrointestinal disorder likely to influence drug
             absorption.

          -  Receipt of regular medication within 14 days prior to the first dose of IMP (including
             high dose vitamins, dietary supplements or herbal remedies).

          -  Receipt of any vaccination within 14 days prior to the first dose of IMP.

          -  Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or
             metabolic dysfunction.

          -  Presence of clinically significant infections (systemic fungal and viral infections,
             acute bacterial infections).

          -  Current or previous history of tuberculosis.

          -  A clinically significant history of previous allergy / sensitivity to hydrocortisone
             and/or dexamethasone.

          -  A clinically significant history or family history of psychiatric disorders/illnesses.

          -  A clinically significant history of drug or alcohol abuse.

          -  Inability to communicate well with the Investigator (i.e., language problem, poor
             mental development or impaired cerebral function).

          -  Participated in a New Chemical Entity clinical study within the previous 4 months or a
             marketed drug clinical study within the previous 3 months. (N.B. The washout period
             between trials was defined as the period of time elapsed between the last dose of the
             previous study and the first dose of the next study).

          -  Subjects who had consumed more than 2 units of alcohol per day within 7 days prior to
             the first dose of IMP or had consumed any alcohol within the 48 hr period prior to the
             first dose of IMP.

          -  Donation of 450 mL or more of blood within the previous 3 months.

          -  Subjects who smoked (or ex-smokers who had smoked within 6 months prior to first dose
             of IMP).

          -  Subjects who worked shifts (i.e. regularly alternated between days, afternoons and
             nights).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Girish Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simbec Research</affiliation>
  </overall_official>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>May 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <results_first_submitted>February 9, 2017</results_first_submitted>
  <results_first_submitted_qc>August 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2017</results_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Area: United Kingdom Location: Phase 1 Unit</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>5-way crossover study design involving Infacort and hydrocortisone at the following dose strengths:
Infacort 0.5mg Infacort 2mg Infacort 5mg Infacort 10mg Hydrocortisone 10mg
Each IMP was administered to each subject in a randomised, crossover manner over 5 treatment periods (1 treatment/period). During each treatment period, each subject was admitted to the Unit on the afternoon of Day 1 and remained in the Unit until completion of all scheduled assessments on Day 2. Each subject received their scheduled IMP on the morning of Day 2 at ~0700hrs (fasted). Each subject also received 1mg dexamethasone (to suppress endogenous cortisol production) at approximately 2200hrs on Day 1, and at approximately 0600hrs and 1200hrs on Day 2. All doses were administered with 200mL water. There were at least 7 days washout between each dose of IMP.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>5-way crossover study design involving Infacort and hydrocortisone at the following dose strengths:
Infacort 0.5mg Infacort 2mg Infacort 5mg Infacort 10mg Hydrocortisone 10mg
Each IMP was administered to each subject in a randomised, crossover manner over 5 treatment periods (1 treatment/period). During each treatment period, each subject was admitted to the Unit on the afternoon of Day 1 and remained in the Unit until completion of all scheduled assessments on Day 2. Each subject received their scheduled IMP on the morning of Day 2 at ~0700hrs (fasted). Each subject also received 1mg dexamethasone (to suppress endogenous cortisol production) at approximately 2200hrs on Day 1, and at approximately 0600hrs and 1200hrs on Day 2. All doses were administered with 200mL water. There were at least 7 days washout between each dose of IMP.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.70" spread="14.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>United Kingdom</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.34" spread="2.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (m)</title>
          <units>Metres (m)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.773" spread="0.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>Kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.70" spread="8.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical History and Concurrent Conditions</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drug/Alcohol and HIV/Hepatitis Screening</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Infacort vs Hydrocortisone</title>
        <description>To compare the Cmax of Infacort® versus immediate-release hydrocortisone in a single dose of 10 mg.</description>
        <time_frame>-1h, -0.5h, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, 6h, 6.5h, 7h, 7.5h, 8h, 9h, 10h, 11h, 12h</time_frame>
        <population>Two subjects were excluded from the Infacort 10mg analysis population due to inadequate endogenous cortisol suppression prior to dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Infacort 10mg</title>
            <description>Multi-particulate granules from 10mg Infacort capsule</description>
          </group>
          <group group_id="O2">
            <title>Hydrocortisone</title>
            <description>1 (10 mg) tablet
Hydrocortisone: Tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Infacort vs Hydrocortisone</title>
          <description>To compare the Cmax of Infacort® versus immediate-release hydrocortisone in a single dose of 10 mg.</description>
          <population>Two subjects were excluded from the Infacort 10mg analysis population due to inadequate endogenous cortisol suppression prior to dosing.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="601.843" spread="21.5"/>
                    <measurement group_id="O2" value="622.384" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach the Maximum Plasma Concentration (Tmax) of Infacort vs Hydrocortisone</title>
        <description>To compare the Tmax of Infacort® versus immediate-release hydrocortisone in a single dose of 10 mg.</description>
        <time_frame>-1h, -0.5h, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, 6h, 6.5h, 7h, 7.5h, 8h, 9h, 10h, 11h, 12h</time_frame>
        <population>Two subjects were excluded from the Infacort 10mg analysis population due to inadequate endogenous cortisol suppression prior to dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Infacort 10mg</title>
            <description>Multi-particulate granules from a 10mg Infacort capsule.</description>
          </group>
          <group group_id="O2">
            <title>Hydrocortisone</title>
            <description>10 mg hydrocortisone tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Maximum Plasma Concentration (Tmax) of Infacort vs Hydrocortisone</title>
          <description>To compare the Tmax of Infacort® versus immediate-release hydrocortisone in a single dose of 10 mg.</description>
          <population>Two subjects were excluded from the Infacort 10mg analysis population due to inadequate endogenous cortisol suppression prior to dosing.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.500" spread="0.4031"/>
                    <measurement group_id="O2" value="1" spread="0.4171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC0-t) of Infacort vs Hydrocortisone</title>
        <description>To compare the AUC0-t of Infacort® versus immediate-release hydrocortisone in a single dose of 10 mg. AUC0-t represents the total exposure to drug over time, hence the reporting of a single value below.</description>
        <time_frame>-1h, -0.5h, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, 6h, 6.5h, 7h, 7.5h, 8h, 9h, 10h, 11h, 12h</time_frame>
        <population>Two subjects were excluded from the Infacort 10mg analysis population due to inadequate endogenous cortisol suppression prior to dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Infacort 10 mg</title>
            <description>Multi-particulate granules from 1 Infacort 10 mg capsule</description>
          </group>
          <group group_id="O2">
            <title>Hydrocortisone</title>
            <description>1 (10 mg) hydrocortisone tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC0-t) of Infacort vs Hydrocortisone</title>
          <description>To compare the AUC0-t of Infacort® versus immediate-release hydrocortisone in a single dose of 10 mg. AUC0-t represents the total exposure to drug over time, hence the reporting of a single value below.</description>
          <population>Two subjects were excluded from the Infacort 10mg analysis population due to inadequate endogenous cortisol suppression prior to dosing.</population>
          <units>hr*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1836.718" spread="17.8"/>
                    <measurement group_id="O2" value="1803.278" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of Infacort at Doses of 0.5, 2, 5 and 10 mg</title>
        <description>To determine the dose proportionality for Infacort® at doses of 0.5 mg, 2 mg, 5 mg and 10 mg.</description>
        <time_frame>-1h, -0.5h, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, 6h, 6.5h, 7h, 7.5h, 8h, 9h, 10h, 11h, 12h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infacort 0.5mg</title>
            <description>Multi-particulate granules from 1 (0.5 mg) capsule
Infacort: Multi-particulate granules</description>
          </group>
          <group group_id="O2">
            <title>Infacort 2mg</title>
            <description>Multi-particulate granules from 1 (2mg) capsule
Infacort: Multi-particulate granules</description>
          </group>
          <group group_id="O3">
            <title>Infacort 5mg</title>
            <description>Multi-particulate granules from 1 (5mg) capsule
Infacort: Multi-particulate granules</description>
          </group>
          <group group_id="O4">
            <title>Infacort 10mg</title>
            <description>Multi-particulate granules from 1 (10mg) capsule
Infacort: Multi-particulate granules</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Infacort at Doses of 0.5, 2, 5 and 10 mg</title>
          <description>To determine the dose proportionality for Infacort® at doses of 0.5 mg, 2 mg, 5 mg and 10 mg.</description>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.220" spread="22.9"/>
                    <measurement group_id="O2" value="242.798" spread="16.0"/>
                    <measurement group_id="O3" value="424.310" spread="14.8"/>
                    <measurement group_id="O4" value="601.843" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) of Infacort at Doses of 0.5, 2, 5 and 10 mg</title>
        <description>To determine the dose proportionality for Infacort® at doses of 0.5 mg, 2 mg, 5 mg and 10 mg.</description>
        <time_frame>-1h, -0.5h, 0h, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, 6h, 6.5h, 7h, 7.5h, 8h, 9h, 10h, 11h, 12h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infacort 0.5 mg</title>
            <description>Multi-particulate granules from 1 (0.5 mg) capsule
Infacort: Multi-particulate granules</description>
          </group>
          <group group_id="O2">
            <title>Infacort 2 mg</title>
            <description>Multi-particulate granules from 1 (2 mg) capsule
Infacort: Multi-particulate granules</description>
          </group>
          <group group_id="O3">
            <title>Infacort 5 mg</title>
            <description>Multi-particulate granules from 1 (5 mg) capsule
Infacort: Multi-particulate granules</description>
          </group>
          <group group_id="O4">
            <title>Infacort 10 mg</title>
            <description>Multi-particulate granules from 1 (10 mg) capsule
Infacort: Multi-particulate granules</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) of Infacort at Doses of 0.5, 2, 5 and 10 mg</title>
          <description>To determine the dose proportionality for Infacort® at doses of 0.5 mg, 2 mg, 5 mg and 10 mg.</description>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.500" spread="0.2236"/>
                    <measurement group_id="O2" value="0.500" spread="0.3010"/>
                    <measurement group_id="O3" value="0.500" spread="0.3162"/>
                    <measurement group_id="O4" value="0.500" spread="0.4031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC0-t) of Infacort at Doses of 0.5, 2, 5 and 10 mg</title>
        <description>To determine the dose proportionality for Infacort® at doses of 0.5 mg, 2 mg, 5 mg and 10 mg.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infacort 0.5 mg</title>
            <description>Multi-particulate granules from 1 (0.5 mg) capsule
Infacort: Multi-particulate granules</description>
          </group>
          <group group_id="O2">
            <title>Infacort 2 mg</title>
            <description>Multi-particulate granules from 1 (2 mg) capsule
Infacort: Multi-particulate granules</description>
          </group>
          <group group_id="O3">
            <title>Infacort 5 mg</title>
            <description>Multi-particulate granules from 1 (5 mg) capsule
Infacort: Multi-particulate granules</description>
          </group>
          <group group_id="O4">
            <title>Infacort 10 mg</title>
            <description>Multi-particulate granules from 1 (10 mg) capsule
Infacort: Multi-particulate granules</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC0-t) of Infacort at Doses of 0.5, 2, 5 and 10 mg</title>
          <description>To determine the dose proportionality for Infacort® at doses of 0.5 mg, 2 mg, 5 mg and 10 mg.</description>
          <units>H*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326.129" spread="21.3"/>
                    <measurement group_id="O2" value="648.407" spread="16.6"/>
                    <measurement group_id="O3" value="1127.579" spread="15.2"/>
                    <measurement group_id="O4" value="1836.718" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) as Assessed by Medical Dictionary for Regulatory Activities (MedDRA) Dictionary, Version 16.0.</title>
        <description>To assess the safety and tolerability of Infacort® throughout the study. For a full list of TEAEs per arm, please refer to the Adverse Events section.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>5-way crossover study design involving Infacort and hydrocortisone at the following dose strengths:
Infacort 0.5mg Infacort 2mg Infacort 5mg Infacort 10mg Hydrocortisone 10mg
Each IMP was administered to each subject in a randomised, crossover manner over 5 treatment periods (1 treatment/period). During each treatment period, each subject was admitted to the Unit on the afternoon of Day 1 and remained in the Unit until completion of all scheduled assessments on Day 2. Each subject received their scheduled IMP on the morning of Day 2 at ~0700hrs (fasted). Each subject also received 1mg dexamethasone (to suppress endogenous cortisol production) at approximately 2200hrs on Day 1, and at approximately 0600hrs and 1200hrs on Day 2. All doses were administered with 200mL water. There were at least 7 days washout between each dose of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) as Assessed by Medical Dictionary for Regulatory Activities (MedDRA) Dictionary, Version 16.0.</title>
          <description>To assess the safety and tolerability of Infacort® throughout the study. For a full list of TEAEs per arm, please refer to the Adverse Events section.</description>
          <units>TEAEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study start (19 July 2013) to completion (9 September 2013)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Infacort 0.5 mg</title>
          <description>Multi-particulate granules from 1 (0.5 mg) capsule
Infacort: Multi-particulate granules</description>
        </group>
        <group group_id="E2">
          <title>Infacort 2 mg</title>
          <description>Multi-particulate granules from 1 (2 mg) capsule
Infacort: Multi-particulate granules</description>
        </group>
        <group group_id="E3">
          <title>Infacort 5 mg</title>
          <description>Multi-particulate granules from 1 (5 mg) capsule
Infacort: Multi-particulate granules</description>
        </group>
        <group group_id="E4">
          <title>Infacort 10 mg</title>
          <description>Multi-particulate granules from 1 (10 mg) capsule
Infacort: Multi-particulate granules</description>
        </group>
        <group group_id="E5">
          <title>Hydrocortisone</title>
          <description>1 (10 mg) tablet
Hydrocortisone: Tablet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator must obtain written consent from the Sponsor prior to any publication of results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Girish Sharma</name_or_title>
      <organization>Simbec Research Limited</organization>
      <phone>+44 1443 690977</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

